Department of Psychiatry, Postgraduate Institute of Medical Education & Research, Chandigarh 160012, India.
Asian J Psychiatr. 2010 Mar;3(1):16-9. doi: 10.1016/j.ajp.2009.12.002. Epub 2010 Feb 4.
There are few studies from India which have evaluated the usefulness and tolerability of clozapine from India.
To study the sociodemographic profile, clinical profile, comorbidity, side effects and outcome of subjects treated with clozapine.
For this study, the inpatient register was screened to obtain data of all patients admitted to the psychiatric inpatient unit during January 2000 to December 2006 and who were either started or continued on clozapine. Case records of 51 patients were taken up for the study.
Majority of the patients who were started on clozapine were male (80.4%), single (70.6%), unemployed (70.6%), educated up to or beyond 10 years of schooling (86.3%) and belonged to nuclear families (64.7%). More than three-fourth's of them had received two or more adequate antipsychotic trials before being considered for clozapine. The mean dose of clozapine was 298.97mg/day. During the inpatient stay (mean duration 63 days), there was significant reduction (34.7%) in PANSS rating after starting clozapine. Sialorrhoea was the most common side effect, reported by 58.8% of subjects. In terms of long term outcome at a mean duration of 3.99 (SD 3.13) years after starting clozapine, 37 cases were on clozapine at the time of last follow-up. While receiving clozapine, three cases developed leucopenia and four patients developed seizures.
Clozapine leads to reduction in psychopathology and sialorrhoea is the most common side effect reported.
印度很少有研究评估印度生产的氯氮平的实用性和耐受性。
研究接受氯氮平治疗的患者的社会人口学特征、临床特征、合并症、副作用和结局。
在这项研究中,筛选了住院患者登记册,以获取 2000 年 1 月至 2006 年 12 月期间入住精神病住院病房并开始或继续使用氯氮平的所有患者的数据。对 51 例患者的病历进行了研究。
开始使用氯氮平的患者中,大多数为男性(80.4%)、单身(70.6%)、失业(70.6%)、接受过 10 年或以上教育(86.3%)且来自核心家庭(64.7%)。超过四分之三的患者在考虑使用氯氮平之前接受过两种或两种以上的适当抗精神病药物治疗。氯氮平的平均剂量为 298.97mg/天。在住院期间(平均住院时间 63 天),开始使用氯氮平后 PANSS 评分显著下降(34.7%)。流涎是最常见的副作用,58.8%的患者有此症状。在开始使用氯氮平平均 3.99 年(SD 3.13 年)后的长期结局方面,最后一次随访时有 37 例仍在使用氯氮平。在接受氯氮平治疗期间,有 3 例出现白细胞减少,4 例出现癫痫发作。
氯氮平可降低精神病理学症状,流涎是最常见的副作用。